All In Biotech

Drug Trial Radar · NCT05326347

A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia

A Multicenter, Uncontrolled, Open-label Trial to Investigate the Long-term Tolerability, Safety, and Efficacy of Brexpiprazole Once-weekly (QW) Formulation Administered Once Weekly for 52 Weeks in Patients With Schizophrenia

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

247

Actual

Start

May 31, 2022

Primary completion

Aug 26, 2025

Study completion Sep 30, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Confirm the tolerability and safety of long-term administration of the brexpiprazole QW formulation in patients with schizophrenia

Conditions

  • Schizophrenia

Interventions

  • OPC-34712FUM/ Brexpiprazole fumarateDrug

    The treatment will begin with oral administration of 1 tablet of the brexpiprazole QW formulation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The frequency of Adverse EventsTime frame: From baseline to week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hayakawa Clinic

    Kure-shi, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.